Omada Health (OMDA) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Omada Health (NASDAQ: OMDA) recently:

• 8/14/2026 – Omada Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 8/14/2026 – Omada Health had its price target raised by JPMorgan Chase & Co. from $26.00 to $30.00. They now have an “overweight” rating on the stock.
• 8/14/2026 – Omada Health had its price target raised by Citizens Jmp from $27.00 to $32.00. They now have a “market outperform” rating on the stock.
• 8/12/2026 – Omada Health had its price target raised by Robert W. Baird from $15.00 to $25.00. They now have a “neutral” rating on the stock.
• 8/11/2026 – Omada Health was upgraded by Weiss Ratings from “sell (e+)” to “sell (d+)”.
• 8/10/2026 – Omada Health had its price target raised by BTIG Research from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Omada Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Omada Health had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $24.00 price target on the stock.
• 8/3/2026 – Omada Health had its price target raised by Barclays PLC from $20.00 to $25.00. They now have an “overweight” rating on the stock.
• 7/21/2026 – Omada Health had its price target raised by Canaccord Genuity Group Inc. from $24.00 to $28.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Omada Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/20/2026 – Omada Health had its price target raised by Citizens Jmp from $21.00 to $27.00. They now have a “market outperform” rating on the stock.
• 7/18/2026 – Omada Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Omada Health is now covered by BTIG Research. They set a “buy” rating and a $30.00 price target on the stock.
• 7/17/2026 – Omada Health is now covered by BTIG Research. They set a “buy” rating and a $30.00 price target on the stock.
• 7/13/2026 – Omada Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Buying and Selling

In other Omada Health news, CFO Steven L. Cook sold 1,108 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $25.00, for a total value of $27,700.00. Following the completion of the sale, the chief financial officer owned 187,209 shares in the company, valued at approximately $4,680,225. This trade represents a 0.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Wei-Li Shao sold 8,866 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total value of $221,827.32. Following the completion of the sale, the president owned 307,372 shares of the company’s stock, valued at approximately $7,690,447.44. This trade represents a 2.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 255,834 shares of company stock worth $5,398,196. Company insiders own 6.38% of the company’s stock.

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.